ArticleBMC biomedical engineering2025
Effect of peroxybenzoic acid and hydroxybenzoic acid on allergic asthma.
Article in BMC biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePeroxybenzoic acid and hydroxybenzoic acid are phenolic compounds commonly used in cosmetics and pharmaceuticals that have shown potential as anti-inflammatory agents. We compared their effects on allergic airway inflammation and Th2 cytokine responses in a murine model of ovalbumin-induced allergic asthma in Balb/c mice.
methodsTen Balb/c mice were randomly assigned to four groups: control, asthma, asthma treated with peroxybenzoic acid, and asthma treated with hydroxybenzoic acid. Asthma was induced through intraperitoneal sensitization with ovalbumin. Then, the mice received intranasal instillations of either peroxybenzoic acid or hydroxybenzoic acid. Then, lung tissues were harvested for histological staining (H&E, PAS) to assess peribronchial and perivascular inflammatory infiltrates as well as goblet cell hyperplasia. Serum levels of IgE, IL-4, IL-5, and IL-13 were measured using ELISA. Data were analyzed using one-way ANOVA with Tukey’s post-hoc test.
resultsMice treated with hydroxybenzoic acid (the asthma + hydroxybenzoic acid group) showed a significant reduction in both peribronchial and perivascular inflammation. The histopathological scores for this group were markedly lower than those of the untreated asthma group (p < 0.01). Additionally, this group demonstrated a significant decrease in IL-5 levels (p < 0.05), while serum concentrations of IgE, IL-4, and IL-13 remained unchanged (p > 0.05). In contrast, mice in the asthma + peroxybenzoic acid group did not show significant differences in airway inflammation or levels of the measured cytokines and IgE when compared to the untreated asthma group (p > 0.05).
conclusionIn this murine model, hydroxybenzoic acid selectively suppresses eosinophil-driven inflammation and IL-5 production, setting it apart from peroxybenzoic acid and many broad-spectrum anti-inflammatory compounds. These findings support the need for further preclinical and early-phase clinical studies to evaluate hydroxybenzoic acid’s potential as a targeted therapy for allergic asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.